Poly (ADP-Ribose) Polymerase Inhibitors - Pipeline Insight, 2024

This “Poly (ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Poly (ADP-ribose) Polymerase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Poly (ADP-ribose) Polymerase Inhibitors: Understanding

Poly (ADP-ribose) Polymerase Inhibitors: Overview

The PARP inhibitor stops the cancer cells being repaired which causes the cells to die and so reduces tumor growth. In cancers where the tumor suppressor gene is faulty the cancer cells are repaired only by PARP. The PARP repair is incomplete which means the cancer cells DNA is repaired to a point where it just has a small amount of damage and the cancer cells are able to able to grow and divide. If the PARP did not repair the DNA then the cancer cells would have too much damage in its DNA so would trigger its own death. The PARP inhibitors act to stop the cancer cells DNA being repaired by PARP, so the damaged DNA stays at the critical level that causes cell to trigger its own death and therefore inhibits the growth of the tumor.

PARP inhibitors are a class of drugs designed to target the PARP family of enzymes, which play a critical role in DNA repair. These inhibitors typically feature a structural moiety such as 1-hydroxyisoquinoline, chlorthenoxazin, 3-hydroxybenzamide, or 4-amino-1,8-naphthalimide. The PARP enzyme itself is composed of four key domains: a DNA-binding domain with zinc finger motifs, a caspase-cleaved domain, an auto-modification domain, and a catalytic domain. The catalytic domain facilitates the polymerization of ADP-ribose units from NAD+ onto target proteins. PARP inhibitors bind specifically to this catalytic domain, thereby blocking the enzyme's activity and preventing DNA repair, which ultimately leads to cell death in cancers that are heavily dependent on PARP function.

PARP inhibitors are a class of drugs that specifically target PARP enzymes, primarily PARP1, which are essential for repairing DNA single-strand breaks. By inhibiting PARP, these drugs impair the cancer cells' ability to repair DNA, leading to the accumulation of damage and eventual cell death, especially in tumors with existing deficiencies in DNA repair mechanisms, such as those harboring BRCA1 or BRCA2 mutations. This concept, known as synthetic lethality, has made PARP inhibitors highly effective in treating cancers like ovarian and breast cancers, leading to the approval of several PARP inhibitors for clinical use. Furthermore, ongoing research is investigating their potential in treating non-oncological diseases and addressing challenges such as resistance to therapy. PARP inhibitors are a promising therapeutic approach in oncology, leveraging the concept of synthetic lethality to target cancer cells with DNA repair deficiencies, such as those with BRCA mutations. By inhibiting PARPs, which are critical for DNA repair, these drugs lead to the accumulation of DNA damage in tumor cells, resulting in cell death. This strategy has proven effective in treating cancers like ovarian and breast cancer, with PARP inhibitors such as olaparib, rucaparib, and niraparib demonstrating significant clinical efficacy. Beyond oncology, PARP inhibitors show potential in conditions characterized by inflammation and reperfusion injury, where they may help mitigate cellular dysfunction and promote survival by restoring energy homeostasis and reducing necrosis.

“Poly (ADP-ribose) Polymerase Inhibitors - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Poly (ADP-ribose) Polymerase Inhibitors pipeline landscape is provided which includes the disease overview and Poly (ADP-ribose) Polymerase Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Poly (ADP-ribose) Polymerase Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Poly (ADP-ribose) Polymerase Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Poly (ADP-ribose) Polymerase Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Poly (ADP-ribose) Polymerase Inhibitors.

Poly (ADP-ribose) Polymerase Inhibitors Emerging Drugs Chapters

This segment of the Poly (ADP-ribose) Polymerase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Poly (ADP-ribose) Polymerase Inhibitors Emerging Drugs

AZD5305: AstraZeneca

AZD5305 is a potent and selective oral PARP inhibitor (PARPi) that specifically targets and traps PARP1, in contrast to approved PARPis which target both PARP1 and PARP2. Preclinical data suggest that PARP1 inhibition confers antiproliferative effects, while PARP2 inhibition is a major driver of hematological toxicity. Thus, AZD5305 may have an improved therapeutic index with less toxicity. The Phase III PROpel study showed that first-line olaparib plus abiraterone (abi) significantly improved radiographic progression-free survival (rPFS) over abi alone in pts with metastatic castration-resistant prostate cancer (mCRPC) enrolled irrespective of homologous recombination repair (HRR) gene mutations. Currently, the drug is in Phase III stage of its clincal trial for the treatment of Prostate cancer.

Stenoparib: Allarity Therapeutics

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.

ACE86225106: Acerand Therapeutics

ACE-86225106 is a novel, oral, and highly selective inhibitor of poly (ADP-ribose) polymerase 1 (PARP1) developed independently by Acerand Therapeutics. It showed significant inhibitory effect on PARP1 in vitro, which was comparable with the positive controls (Olaparib, the first-generation pan-PARPi, and AZD5305, the second-generation PARP1 selective inhibitor under development), and showed no significant inhibitory effect. ACE-86225106 is expected to uphold its anti-tumor efficacy with potentially reduced hematological toxicity risks (i.e. anemia) and extended therapeutic window, thereby improving the prognosis for patients with advanced solid tumor. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Solid Tumor.

Poly (ADP-ribose) Polymerase Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Poly (ADP-ribose) Polymerase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Poly (ADP-ribose) Polymerase Inhibitors

There are approx. 20+ key companies which are developing the therapies for Poly (ADP-ribose) Polymerase Inhibitors. The companies which have their Poly (ADP-ribose) Polymerase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Phases

The report covers around 22+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Poly (ADP-ribose) Polymerase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as:

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Poly (ADP-ribose) Polymerase Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Poly (ADP-ribose) Polymerase Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Poly (ADP-ribose) Polymerase Inhibitors drugs.

Poly (ADP-ribose) Polymerase Inhibitors Report Insights

• Poly (ADP-ribose) Polymerase Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Poly (ADP-ribose) Polymerase Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Poly (ADP-ribose) Polymerase Inhibitors drugs?
• How many Poly (ADP-ribose) Polymerase Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly (ADP-ribose) Polymerase Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly (ADP-ribose) Polymerase Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Poly (ADP-ribose) Polymerase Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Chengdu Baiyu Pharmaceutical
• Gilead Sciences
• Chia Tai Tianqing Pharmaceutical
• Duke Street Bio
• Eikon Therapeutics
• Acerand Therapeutics
• Allarity Therapeutics
• Jiangsu Hengrui Medicine
• AstraZeneca

Key Products

• BY 101921
• GS 0201
• TQB3823
• DSB 1559
• EIK1003
• ACE86225106
• Stenoparib
• HRS 1167
• AZD5305

This product will be delivered within 1-3 business days.